We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+33.35%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.6B
AUM Growth
+$504M
Cap. Flow
+$116M
Cap. Flow %
4.45%
Top 10 Hldgs %
62.82%
Holding
68
New
12
Increased
10
Reduced
11
Closed
26

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$90.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$86M
3
PTCT icon
PTC Therapeutics
PTCT
+$71.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$69.4M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$63.4M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$83.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.5M
3
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$45.2M
4
DVAX
Dynavax Technologies
DVAX
+$32.8M
5
ARRY
Array Biopharma Inc
ARRY
+$31.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$419M 16.14%
17,714,461
+775,000
+5% +$15.6M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$237M 9.11%
4,798,101
+400,000
+9% +$15.1M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.5B
$153M 5.88%
1,622,770
-88,225
-5% -$7.73M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$146M 5.63%
9,369,150
-136,297
-1% -$2.06M
ASND icon
5
Ascendis Pharma A/S
ASND
$15.1B
$137M 5.28%
2,063,336
– –
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12B
$137M 5.27%
+489,536
New +$86M
SRPT icon
7
Sarepta Therapeutics
SRPT
$2.18B
$127M 4.88%
+958,928
New +$90.4M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$4.1B
$105M 4.03%
8,177,720
+99,215
+1% +$1.45M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$92.6M 3.57%
5,593,683
+435,000
+8% +$6.63M
ECYT
10
DELISTED
Endocyte, Inc. Common Stock
ECYT
$78.6M 3.03%
5,695,200
– –
PTCT icon
11
PTC Therapeutics
PTCT
$5.45B
$77.4M 2.98%
+2,294,877
New +$71.6M
SPPI
12
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$71.7M 2.76%
+3,419,818
New +$63.4M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$32.5B
$69M 2.65%
+700,100
New +$69.4M
ZGNX
14
DELISTED
Zogenix, Inc.
ZGNX
$66.4M 2.56%
1,503,313
+314,100
+26% +$12.9M
TGTX icon
15
TG Therapeutics
TGTX
$8.11B
$65.1M 2.51%
4,950,031
-279,588
-5% -$3.85M
ARGX icon
16
argenx
ARGX
$61.8B
$64.8M 2.49%
782,053
-81,222
-9% -$7.26M
PBYI icon
17
Puma Biotechnology
PBYI
$479M
$61.2M 2.36%
1,034,375
+209,007
+25% +$12.1M
VNDA icon
18
Vanda Pharmaceuticals
VNDA
$303M
$53.3M 2.05%
2,800,191
+25,000
+0.9% +$418K
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$52.1M 2.01%
1,146,436
-19,448
-2% -$946K
PCRX icon
20
Pacira BioSciences
PCRX
$954M
$46.8M 1.8%
1,460,610
-254,462
-15% -$8.79M
VKTX icon
21
Viking Therapeutics
VKTX
$3.49B
$42.4M 1.63%
+4,471,300
New +$29.7M
ASMB icon
22
Assembly Biosciences
ASMB
$557M
$37.8M 1.45%
80,286
-10,875
-12% -$5.75M
MDCO
23
DELISTED
Medicines Co
MDCO
$35.3M 1.36%
961,574
-674,243
-41% -$21.9M
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
$32.8M 1.26%
+1,095,764
New +$30.6M
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$31.7M 1.22%
700,548
-1,065,000
-60% -$48.5M
1
2 3

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Avoro Capital Advisors held 68 positions worth $2.6B, up 24% from $2.09B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $116M of net new capital in Q2 2018, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 958,928 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $48.5M trimmed.

  • Avoro Capital Advisors's largest Q2 2018 buy was Sarepta Therapeutics: 958,928 shares worth $127M.
  • Avoro Capital Advisors added most to Immunomedics Inc in Q2 2018, an estimated $15.6M increase.
  • Avoro Capital Advisors's biggest Q2 2018 reduction was Global Blood Therapeutics, Inc., cutting an estimated $48.5M.
  • Avoro Capital Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $83.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $2.6B portfolio in Q2 2018.
  • Avoro Capital Advisors opened 12 new positions and closed 26 in Q2 2018.
  • Avoro Capital Advisors's portfolio value rose 24% quarter-over-quarter to $2.6B.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.